Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

37
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
37
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

369
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

334
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
334

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomic Signatures of <i>Trichomonas vaginalis</i> Isolates That Exhibit Low, Intermediate, and High In Vitro Resistance to Metronidazole.

Microorganisms·2026
Same author

Sex-specific presentation, epidemiology, and control of schistosomiasis in women and adolescent girls.

The Lancet. Global health·2026
Same author

Association of Schistosoma haematobium Infection With Decreased Pregnancy: A Prospective Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Development and Validation of an ELISA to Detect Antibody to Onchocerca volvulus Infection Using Mammalian Expressed Recombinant Ov16.

The American journal of tropical medicine and hygiene·2026
Same author

AID-FGS: Artificial intelligence-enabled diagnosis of female genital schistosomiasis: Preliminary findings.

PLOS digital health·2026
Same author

Response to STD-2025-175: Letter to the Editor.

Sexually transmitted diseases·2025

Related Experiment Video

Updated: Mar 24, 2026

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni
12:05

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

10.0K

Early lessons from schistosomiasis mass drug administration programs.

W Evan Secor1

  • 1Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.

F1000Research
|March 4, 2016
PubMed
Summary

Mass drug administration with praziquantel is key for schistosomiasis control, but challenges necessitate adjuncts and new tools for effective elimination strategies.

Keywords:
mass drug administrationpraziquantelschistosomeschistosomiasis

More Related Videos

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules
05:30

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

18.8K
Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation
09:58

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation

Published on: June 5, 2012

14.4K

Related Experiment Videos

Last Updated: Mar 24, 2026

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni
12:05

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

10.0K
Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules
05:30

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

18.8K
Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation
09:58

Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation

Published on: June 5, 2012

14.4K

Area of Science:

  • Public Health
  • Infectious Disease Control
  • Tropical Medicine

Background:

  • Mass drug administration (MDA) with praziquantel is the primary strategy for schistosomiasis control.
  • Current MDA approaches face challenges, potentially limiting the achievement of program goals.
  • Schistosomiasis remains endemic in diverse settings, requiring adaptable control interventions.

Purpose of the Study:

  • To review challenges and opportunities in schistosomiasis control programs.
  • To explore adjuncts to mass drug administration for improved public health impact.
  • To discuss the integration of new diagnostics and praziquantel formulations.

Main Methods:

  • Literature review of schistosomiasis control strategies.
  • Analysis of current mass drug administration effectiveness and limitations.
  • Exploration of potential adjunct interventions and technological advancements.

Main Results:

  • Annual MDA alone may be insufficient for schistosomiasis elimination.
  • Adjunct interventions are crucial for enhancing MDA efficacy.
  • New diagnostic tools and praziquantel formulations can improve treatment accessibility and targeting.

Conclusions:

  • Improving schistosomiasis control requires optimizing MDA and integrating novel approaches.
  • Strategic use of adjuncts, diagnostics, and drug formulations is essential for moving towards elimination goals.
  • Continued research and program adaptation are vital for maximizing public health impact.